HK1071379A1 - Long lasting fusion peptide inhibitors for hiv infection - Google Patents

Long lasting fusion peptide inhibitors for hiv infection

Info

Publication number
HK1071379A1
HK1071379A1 HK05104106A HK05104106A HK1071379A1 HK 1071379 A1 HK1071379 A1 HK 1071379A1 HK 05104106 A HK05104106 A HK 05104106A HK 05104106 A HK05104106 A HK 05104106A HK 1071379 A1 HK1071379 A1 HK 1071379A1
Authority
HK
Hong Kong
Prior art keywords
virus
hiv infection
long lasting
fusion peptide
peptide inhibitors
Prior art date
Application number
HK05104106A
Other languages
English (en)
Inventor
John Erickson
Dominique P Bridon
Martin Robitaille
Grant A Krafft
Dong Xie
Elena Afonina
Liangjun
Sandra De Meyer
Original Assignee
John Erickson
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Erickson, Conjuchem Biotechnologies Inc filed Critical John Erickson
Publication of HK1071379A1 publication Critical patent/HK1071379A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05104106A 2001-05-31 2005-05-17 Long lasting fusion peptide inhibitors for hiv infection HK1071379A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31

Publications (1)

Publication Number Publication Date
HK1071379A1 true HK1071379A1 (en) 2005-07-15

Family

ID=23132509

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104106A HK1071379A1 (en) 2001-05-31 2005-05-17 Long lasting fusion peptide inhibitors for hiv infection

Country Status (12)

Country Link
US (2) US7741453B2 (fr)
EP (1) EP1390399B1 (fr)
JP (2) JP4463545B2 (fr)
AT (3) ATE412667T1 (fr)
AU (1) AU2002302277A1 (fr)
CA (1) CA2448891A1 (fr)
DE (3) DE60216151T2 (fr)
DK (1) DK1479691T3 (fr)
ES (2) ES2242860T3 (fr)
HK (1) HK1071379A1 (fr)
PT (1) PT1479691E (fr)
WO (1) WO2002096935A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1264840T3 (da) * 1999-05-17 2009-11-16 Conjuchem Biotechnologies Inc Langtidsvirkende fusionspeptidinhibitorer af viral infektion
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
CA2520257A1 (fr) * 2003-03-24 2004-10-07 Sequoia Pharmaceuticals, Inc. Conjugues actifs sur le plan biologique a action prolongee
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
WO2005056752A2 (fr) 2003-10-24 2005-06-23 Gencia Corporation Procedes et compositions permettant de distribuer des polynucleotides
CN1956998B (zh) * 2004-04-23 2012-12-12 康久有限责任公司 用于纯化白蛋白结合物的方法
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
EP2147016A2 (fr) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Dérivés d'acide cystéique de peptides antiviraux
WO2008144590A2 (fr) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Inhibiteurs d'infection virale à longue durée d'action
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
CA3062003C (fr) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamine d comme un groupe cible de peptides therapeutiques
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (fr) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Conjugués de vitamine d thérapeutiques

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ES2139017T3 (es) * 1992-07-20 2000-02-01 Univ Duke Compuestos que inhiben la replicacion del vih.
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (fr) 1992-12-04 1999-08-25 ConjuChem, Inc. Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1996005389A1 (fr) 1994-08-15 1996-02-22 B-Level Corp. Dispositif de formation de surface auxiliaire pour elements de construction
ES2299177T3 (es) * 1995-05-10 2008-05-16 Kyowa Hakko Kogyo Co., Ltd. Conjugados de citotoxinas que contienen dipeptidos.
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
DE69839946D1 (de) 1997-11-07 2008-10-09 Conjuchem Biotechnologies Inc Methoden zum Screening von Affinitätsmarker-Bibliotheken
ES2173641T3 (es) 1997-11-07 2002-10-16 Conjuchem Inc Composicion de derivados opiaceos para la fabricacion de medicamentos.
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
JP2002512640A (ja) 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
DE69926009D1 (de) * 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
WO2000040616A1 (fr) 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1
DK1264840T3 (da) * 1999-05-17 2009-11-16 Conjuchem Biotechnologies Inc Langtidsvirkende fusionspeptidinhibitorer af viral infektion
EP1171582A2 (fr) 1999-05-17 2002-01-16 Conjuchem, Inc. Peptides antiangiogeniques durables
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2623458A1 (fr) 1999-05-17 2000-11-23 Conjuchem Biotechnologies Inc. Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
WO2001017568A2 (fr) 1999-09-07 2001-03-15 Conjuchem, Inc. Diffusion pulmonaire permettant la bioconjugaison
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
DE60037450T2 (de) 1999-12-16 2008-12-04 Whitehead Institute For Biomedical Research, Cambridge Fünf-helix protein
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
CA2500248C (fr) 2002-09-24 2013-03-19 Frontier Biotechnologies Co., Ltd. Inhibiteurs de fusion contre l'infection au vih derives de peptides
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
WO2004028473A2 (fr) 2002-09-27 2004-04-08 Tanox, Inc. Compositions synergetiques pour la prevention et le traitement du syndrome d'immunodeficience acquise
US20050113292A1 (en) 2003-07-18 2005-05-26 Vanderbilt University Compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like
CN1956998B (zh) 2004-04-23 2012-12-12 康久有限责任公司 用于纯化白蛋白结合物的方法
US20080039532A1 (en) 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
CN101384623B (zh) 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法

Also Published As

Publication number Publication date
ATE345353T1 (de) 2006-12-15
DE60216151D1 (de) 2006-12-28
ATE412667T1 (de) 2008-11-15
EP1390399B1 (fr) 2005-05-11
CA2448891A1 (fr) 2002-12-05
US20050065075A1 (en) 2005-03-24
WO2002096935A2 (fr) 2002-12-05
WO2002096935A3 (fr) 2003-10-02
DE60204137T2 (de) 2006-01-26
AU2002302277A1 (en) 2002-12-09
DE60204137D1 (de) 2005-06-16
ES2277173T3 (es) 2007-07-01
DE60229677D1 (de) 2008-12-11
JP2005500274A (ja) 2005-01-06
ATE295370T1 (de) 2005-05-15
JP2008308506A (ja) 2008-12-25
US20110166061A1 (en) 2011-07-07
DK1479691T3 (da) 2007-03-12
EP1390399A2 (fr) 2004-02-25
ES2242860T3 (es) 2005-11-16
PT1479691E (pt) 2007-02-28
US7741453B2 (en) 2010-06-22
JP4463545B2 (ja) 2010-05-19
DE60216151T2 (de) 2007-09-27

Similar Documents

Publication Publication Date Title
HK1071379A1 (en) Long lasting fusion peptide inhibitors for hiv infection
WO2008144584A3 (fr) Dérivés d'acide cystéique de peptides antiviraux
ATE387208T1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
WO2005007078A3 (fr) Methodes d'inhibition du metapneumovirus humain et du coronavirus humain dans la prevention et le traitement du sras
WO2003051306A3 (fr) Nucleosides de n4-acylcytosine-1,3-dioxolane destines au traitement d'infections virales
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
EA200700243A1 (ru) Способы лечения гепатита с
DE602006015861D1 (de) Antivirale verbindungen
WO2007033444A3 (fr) Nouveaux traitements antiviraux
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
WO2003053344A3 (fr) 2-methyl-benzimidazole substitues en tant qu'agents antiviraux du virus respiratoire syncytial
EP0652011A4 (fr) Agent prophylactique et agent curatif contre des maladies virales des voies respiratoires.
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
WO2006045616A3 (fr) $g(b)-l-n4-hydroxycytosine desoxynucleosides et leur utilisation comme agents pharmaceutiques dans la prophylaxie ou le traitement de maladies virales
WO2007002172A3 (fr) Inhibiteurs de la protease du vih-1
WO2004052905A3 (fr) Derives de nucleoside antiviraux
EP1752469A3 (fr) Inhibiteurs peptidiques de fusion longue durée contre les infections à VIH
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
WO2008144590A3 (fr) Inhibiteurs d'infection virale à longue durée d'action
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
ATE375800T1 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen
WO2001030325A3 (fr) Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120531